Form 4: Heartflow Director Converts Notes, Acquires Options

Heartflow Director Timothy C. Barabe converted convertible promissory notes into common stock and was granted new stock options.

Summary

• Director Timothy C. Barabe converted 131,578 shares of convertible promissory notes into common stock on August 11, 2025.
• The conversion occurred automatically upon Heartflow, Inc.'s initial public offering (IPO).
• The conversion price was 80% of the IPO price per share, subject to a valuation ceiling of $2.0 billion.
• Barabe was granted 23,710 stock options on August 7, 2025, with an exercise price of $19.
• These options will vest in full on the earlier of Heartflow's annual meeting in 2026 or the first anniversary of the grant date (August 7, 2025), contingent on continued service.
• Following these transactions, Barabe directly beneficially owns 168,357 shares of common stock and 23,710 stock options.

Sentiment

Score: 7

Explanation: The filing indicates routine post-IPO transactions and ongoing director compensation, which are generally positive for governance and alignment of interests, without any negative surprises.

Positives

• Director Barabe's acquisition of 23,710 stock options indicates continued alignment of his interests with shareholder value.
• The conversion of convertible notes into common stock simplifies the capital structure and reflects the completion of the IPO.

Future Outlook

The vesting schedule for the newly granted stock options extends to the earlier of Heartflow's annual meeting in 2026 or August 7, 2026, indicating a future incentive for continued service.

Industry Context

This filing reflects standard equity compensation practices for directors following an IPO, aligning management incentives with long-term company performance. The conversion of notes is a typical post-IPO event, simplifying the capital structure.

Comparison to Industry Standards

• The grant of stock options to a director is a common practice in the technology and healthcare sectors, particularly post-IPO, to incentivize long-term commitment and performance. The vesting schedule (one year or by next annual meeting) is also standard for such grants, comparable to practices seen at companies like Moderna (MRNA) or Snowflake (SNOW) post-IPO for their non-employee directors.
• The conversion of convertible notes at a discount to the IPO price (80%) is a common feature for early investors or noteholders, reflecting their initial risk, a mechanism often observed in venture-backed companies transitioning to public markets.

Related Party Transactions

• Conversion of convertible promissory notes held by Director Timothy C. Barabe into common stock upon the company's IPO.

Stakeholder Impact

• Shareholders: Increased alignment of Director Barabe's interests with shareholders through common stock ownership and stock options.

Next Steps

• The stock options will vest in full on the earlier of Heartflow's annual meeting in 2026 or August 7, 2026, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details routine post-IPO equity transactions for a director, including the conversion of convertible notes and the grant of stock options. These actions are standard for aligning management incentives with shareholder interests and do not present new information that would fundamentally alter the investment thesis for Heartflow, Inc. Therefore, a 'hold' recommendation is appropriate as there are no strong catalysts for 'buy' or 'sell' based solely on this filing.

Keywords

Heartflow, HTFL, Timothy C. Barabe, Director, SEC Form 4, Beneficial Ownership, Stock Options, Convertible Notes, IPO, Equity Compensation